Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Impacto del consumo de uva en polvo en la salud ocular y el estado glucémico en adultos mayores de Singapur

10 de noviembre de 2026 actualizado por: Jung Eun Kim, National University of Singapore

Impacto del consumo regular de uva en la salud ocular y la regulación de los productos finales de glicación avanzada en adultos mayores de Singapur

The purpose of this study is to understand the impacts of regular consumption of freeze-dried table grape powder on eye health and regulation of advanced glycation end products in Singapore older adults. The investigators hypothesize that regular consumption of freeze-dried table grape powder will promote improvements in eye health and lower levels of advanced glycation end products when compared to the placebo group.

Descripción general del estudio

Descripción detallada

The study will be a 16-week, double-blind, randomized, placebo-controlled trial using a parallel study design. 46 adults (aged 60 - 85) will be recruited and randomly assigned to the intervention or placebo group to investigate whether regular consumption of freeze-dried table grape powder (46g/d) can improve eye health parameters, blood/skin AGE and glycemic status, and reduce inflammation and oxidative stress. This study will consist of 1 screening visit and 5 study visits with 4-week intervals.

Tipo de estudio

Intervencionista

Inscripción (Actual)

43

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Singapore
      • Singapore, Singapore, Singapur, 117550
        • National University of Singapore, Faculty of Science, Department of Food Science and Technology

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

60 años a 85 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

Sí

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. Male and female participants, aged between 60 and 85 years old inclusive
  2. English-literate and able to give informed consent in English

Exclusion Criteria:

  1. Smokers
  2. Allergy to grapes or food dyes/additives, or had serious food allergies in the past
  3. Known eye diseases (macular degeneration, cataracts, retinopathy or glaucoma), blindness in at least one eye or have had eye surgery
  4. Unable to view bright lights or flashing lights
  5. Has Type 1 or 2 diabetes, uremia, cardiovascular disease, abnormal kidney and liver function
  6. Taking eye medication and/or dietary supplements for the eyes for the past 3 month
  7. Taking supplements containing carotenoids (e.g. Vitamin A, lutein, zeaxanthin) for past 3 months
  8. Currently on a specialised diet (e.g. vegetarian, vegan, weight loss diet, low fat diet
  9. Consumes more than 2 alcoholic drinks per day i.e. one drink is defined as either 150ml of wine,340ml of beer/cider or 45ml of distilled spirit
  10. Significant change in weight (≥ 3 kg body weight) in the past 3 months
  11. Significant exercise pattern over the past 3 months defined as high-intensity exercise of more than 3 hours per week
  12. Currently on anti-hypertensive, cholesterol-lowering or psychoactive drugs
  13. Scored ≤ 7 on the abbreviated mental test
  14. Poor peripheral venous access based on past experiences with blood draw
  15. Participating in another clinical study

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Prevención
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Doble

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Freeze-dried table grape powder

Subjects in this group will be given pouches, each containing 46 g of freeze-dried table grape powder, with an instruction sheet on how to prepare the powder into a drink for consumption.They will consume one pouch a day.

Consumption of grape powder as part of daily diet

Comparador de placebos: Placebo table grape powder

Subjects in this group will be given pouches, each containing 46 g of placebo grape powder, with an instruction sheet on how to prepare the powder into a drink for consumption.They will consume one pouch a day.

Consumption of placebo grape powder as part of daily diet

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Macular pigment optical density
Periodo de tiempo: Week 0, Week 4, Week 8, Week 12, Week 16

A measurement of macular pigment of the eye using a heterochromatic flicker photometry device. The measurements are in arbitrary units.

Week 0, Week 4, Week 8, Week 12, Week 16
Visual acuity
Periodo de tiempo: Week 0, Week 4, Week 8, Week 12, Week 16

Participants will read out letters on a ETDRS LogMAR chart at a fixed distance where letters becomes smaller as it goes down the chart. Tests results will be recorded in number of letters read, where the more letters the better the outcome.

Week 0, Week 4, Week 8, Week 12, Week 16
Photostress recovery time
Periodo de tiempo: Week 0, Week 4, Week 8, Week 12, Week 16

An ophthalmoscope will be used to shine a light into the participants eye for 10 seconds, and participants will be required to read letters off a chart the moment their vision returns to normal. The faster the recovery time, the better the outcome. Units will be in seconds

Week 0, Week 4, Week 8, Week 12, Week 16
Visual function questionnaire 25
Periodo de tiempo: Week 0, Week 4, Week 8, Week 12, Week 16

A questionnaire to for participants to self-evaluate their perception of their current eye health based on general vision, ocular pain, near activities, distance activities, vision specific functions, driving, color vision and peripheral vision. The best possible score is 100 and worst possible score is 0.

Week 0, Week 4, Week 8, Week 12, Week 16
Skin advanced glycation end products levels
Periodo de tiempo: Week 0, Week 4, Week 8, Week 12, Week 16

Measurement of skin advanced glycation end products level using a skin autofluorescence device, where participants wlll be instructed to place their forearm over the device and a light will be shone and a reading can be captured by detecting fluorescence. The results will be presented as arbitrary units.

Week 0, Week 4, Week 8, Week 12, Week 16
Dietary advanced glycation end products level
Periodo de tiempo: Week 0, Week 4, Week 8, Week 12, Week 16

Participants will be instructed to record down 3-day food records, from Thursday to Saturday, before each clinical visit. This will be used to estimate their advanced glycation end products intake from food by referring to existing nutrient databases. Units will be based on a common advanced glycation end product measured, carboxymethyllysine (CML), thus the unit will be mg CML/ kg food

Week 0, Week 4, Week 8, Week 12, Week 16
Blood advanced glycation end products levels
Periodo de tiempo: Week 0, Week 8 and Week 16

Participants will have their blood drawn by medical professionals at the Occupational Health Clinic. The blood will be processed and stored. Measurements will be done using ultra-performance liquid chromatography coupled with mass spectrometry techniques to determine the levels of advanced glycation end products. Units will be in μg/mL.

Week 0, Week 8 and Week 16
Contrast sensitivity
Periodo de tiempo: Week 0, Week 4, Week 8, Week 12, Week 16

Participants will read out letters on a ETDRS LogMAR chart at a fixed distance, where the letters differs in lightness to test participants' sensitivity to contrast. Tests results will be recorded in number of letters read, where the more letters the better the outcome.

Week 0, Week 4, Week 8, Week 12, Week 16

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Concentration of tumour necrosis factor-α
Periodo de tiempo: Week 0, Week 8, Week 16

The blood obtained from the participants will be processed for storage. Tumor necrosis factor-α results will be presented in ng/L according to the commercially available enzyme-linked immunosorbent assay kits.

Week 0, Week 8, Week 16
Concentration of interleukin-6
Periodo de tiempo: Week 0, Week 8, Week 16

The blood obtained from the participants will be processed for storage. Interleukin-6 results will be presented in ng/L according to the commercially available enzyme-linked immunosorbent assay kits.

Week 0, Week 8, Week 16
Concentration of high-sensitivity C-reactive protein
Periodo de tiempo: Week 0, Week 8, Week 16

The blood obtained from the participants will be processed for storage. Analyses of inflammation markers include tumor necrosis factor-α, interleukin-6. high sensitivity C-reactive protein. Tumor necrosis factor-α and interleukin-6 results will be presented in ng/L according to the commercially available enzyme-linked immunosorbent assay kits. High-sensitivity C-reactive protein results will be obtained and presented in mg/L by commercial lab testing.

Week 0, Week 8, Week 16
Concentration of fasting blood glucose
Periodo de tiempo: Week 0, Week 8, Week 16

Fasting blood glucose will be measured using commercial lab testing using participants' blood, units will be in mmol/L.

Week 0, Week 8, Week 16
Concentration of malondialdehyde
Periodo de tiempo: Week 0, Week 8, Week 16

The blood obtained from the participants will be processed for storage. Analyses of malondialdehyde using commercially available enzyme-linked immunosorbent assay kits. Units for malondialdehyde will be in ng/L according to assay kit instructions.

Week 0, Week 8, Week 16
Concentration of 8-isoprostaglandin-F2α
Periodo de tiempo: Week 0, Week 8, Week 16

The blood obtained from the participants will be processed for storage. Analyses of 8-isoprostaglandin-F2α using commercially available enzyme-linked immunosorbent assay kits. Units for 8-isoprostaglandin-F2α will be in µmol/L according to assay kit instructions.

Week 0, Week 8, Week 16
Skin carotenoid status
Periodo de tiempo: Week 0, Week 4, Week 8, Week 12, Week 16;

Measured using a commercially available device that measured carotenoids using Raman spectroscopy. Results are in arbitrary units.

Week 0, Week 4, Week 8, Week 12, Week 16;
Concentration of insulin
Periodo de tiempo: Week 0, Week 8, Week 16

Fasting blood insulin will be measured using commercial lab testing using participants' blood, units in μU/L.

Week 0, Week 8, Week 16
Percentage of glycated hemoglobin
Periodo de tiempo: Week 0, Week 8, Week 16

Glycated hemoglobin will be measured using commercial lab testing from participant's blood, units in percent.

Week 0, Week 8, Week 16

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
Measurement of height
Periodo de tiempo: Week 0, Week 4, Week 8, Week 12, Week 16

Height will be measured using height-weight scale and units will be in cm.

Week 0, Week 4, Week 8, Week 12, Week 16
Measurement of blood pressure
Periodo de tiempo: Week 0, Week 4, Week 8, Week 12, Week 16

A blood pressure monitoring device available commercially will be used be to measure their systolic nad diastolic blood pressure.

Week 0, Week 4, Week 8, Week 12, Week 16
Measurement of weight
Periodo de tiempo: Week 0, Week 4, Week 8, Week 12, Week 16

Weight will be measured using height-weight scale and units will be in kg.

Week 0, Week 4, Week 8, Week 12, Week 16
Measurement of waist circumference
Periodo de tiempo: Week 0, Week 4, Week 8, Week 12, Week 16

Waist circumference will be measured using a measuring tape by a trained personnel, units in cm.

Week 0, Week 4, Week 8, Week 12, Week 16

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Jung Eun Kim, Ph.D., R.D., National University of Singapore

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

30 de septiembre de 2024

Finalización primaria (Actual)

11 de febrero de 2026

Finalización del estudio (Actual)

11 de febrero de 2026

Fechas de registro del estudio

Enviado por primera vez

14 de marzo de 2024

Primero enviado que cumplió con los criterios de control de calidad

4 de abril de 2024

Publicado por primera vez (Actual)

5 de abril de 2024

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

16 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

10 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • S25

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Descripción del plan IPD

Electronic copies of the data with identifiable participant information will be kept on NUS OneDrive with access limited only Dr Kim Jung Eun and her research staff. All data will be de-identified prior to statistical analyses.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir